Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 10/20 | 0.52 |
| ▸ | AGXT | P21549 | 7/20 | 0.52 |
| ▸ | NNMT | P40261 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30228073 | 0.84 | KDM1A (0.43) | NNMTKDM1AMAOAMAOBCSF1R | |
| SCHEMBL1257274 | 0.84 | KDM1A (0.43) | NNMTKDM1AMAOAMAOBCSF1R | |
| SCHEMBL16421142 | 0.81 | NNMT (0.49) | NNMTKDM1AMAOAMAOB | |
| SCHEMBL2936144 | 0.80 | AGXT (0.41) | IDO1AGXTCYP3A4 | |
| SCHEMBL1146238 | 0.80 | LOXL2 (0.53) | NNMTKDM1AMAOAMAOB | |
| SCHEMBL29658888 | 0.80 | LOXL2 (0.53) | NNMTKDM1AMAOAMAOB | |
| SCHEMBL5547238 | 0.80 | LOXL2 (0.53) | NNMTKDM1AMAOAMAOB | |
| Ammonia Solution, Strong SCHEMBL6061986 | 0.78 | LOXL2 (0.52) | NNMTKDM1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL6234391 | 0.78 | LOXL2 (0.52) | NNMTKDM1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL5013392 | 0.78 | LOXL2 (0.52) | NNMTKDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190000832-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | Selder Pharma Inc. (US) | 2019-01-03 | — | — | US | disclosed |
| US-10016410-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016410-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170189390-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | SELDAR PHARMA INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170189390-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | SELDAR PHARMA INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-9526719-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9526719-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150359787-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | SELDAR PHARMA INC. (US) | 2015-12-17 | — | — | US | disclosed |
| US-9150541-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150541-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-8486970-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486970-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20100227866-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100227866-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| EP-2040698-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189390-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | BRS3, BDKRB2, NTSR2 | IDO1 1364/4885AGXT 4231/4885NNMT 2621/4885 |
| US-20150359787-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | BRS3, BDKRB2, NTSR2 | IDO1 1364/4885AGXT 4231/4885NNMT 2621/4885 |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | IDO1 305/4885AGXT 3147/4885NNMT 2822/4885 |
| US-10016410-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | BRS3, BDKRB2, NTSR2 | IDO1 1364/4885AGXT 4231/4885NNMT 2621/4885 |
| US-20100227866-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | BRS3, BDKRB2, NTSR2 | IDO1 1501/4885AGXT 4101/4885NNMT 2836/4885 |
| US-20190000832-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | BRS3, BDKRB2, NTSR2 | IDO1 1364/4885AGXT 4231/4885NNMT 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.